Sugi Predict

Sugi Predict / Compounds / SCHEMBL4287556

SCHEMBL4287556

SCHEMBL4287556

COC[C@]1(O)CCCC[C@H]1n1cnc(C(=O)N2CCNC[C@H]2CCOc2ccc3oc(C4CC4)nc3c2)c1-c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.35
▸ HCRTR2 O43614 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ USP19 O94966 2/20 0.34
▸ LMNA P02545 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ TP53 P04637 2/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ HTR2B P41595 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281825 0.93 HCRTR1 (0.38) HCRTR1HCRTR2USP19MEN1KMT2A
SCHEMBL4294404 0.93 HCRTR1 (0.35) HCRTR1HCRTR2POLBUSP19LMNA
SCHEMBL4293022 0.92 HCRTR1 (0.37) HCRTR1HCRTR2POLBUSP19LMNA
SCHEMBL4285006 0.92 MEN1 (0.36) HCRTR1HCRTR2USP19MEN1KMT2A
SCHEMBL4286361 0.89 HCRTR2 (0.38) HCRTR1HCRTR2USP19NPC1RAB9A
SCHEMBL4282038 0.89 HCRTR1 (0.38) HCRTR1HCRTR2USP19MEN1KMT2A
SCHEMBL4293902 0.88 HCRTR1 (0.38) HCRTR1HCRTR2USP19CHEK2
SCHEMBL4295374 0.88 USP19 (0.34) HCRTR1HCRTR2USP19
SCHEMBL4284952 0.88 NPC1 (0.37) HCRTR1HCRTR2USP19MEN1KMT2A
SCHEMBL4289627 0.88 HCRTR1 (0.36) HCRTR1HCRTR2USP19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 — — US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 — — US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT HCRTR1 3147/4885HCRTR2 3136/4885POLB 3799/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT HCRTR1 3147/4885HCRTR2 3136/4885POLB 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.